Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P48023

UPID:
TNFL6_HUMAN

ALTERNATIVE NAMES:
Apoptosis antigen ligand; CD95 ligand; Fas antigen ligand

ALTERNATIVE UPACC:
P48023; Q9BZP9

BACKGROUND:
The protein known as Fas ligand, with alternative names such as Apoptosis antigen ligand and CD95 ligand, is integral to apoptosis and immune regulation. By binding to its receptor TNFRSF6/FAS, it triggers cell death pathways essential for immune homeostasis. Its involvement extends to T-cell apoptosis, contributing to the resolution of immune responses and maintenance of tolerance.

THERAPEUTIC SIGNIFICANCE:
Given its association with Autoimmune lymphoproliferative syndrome 1B, the therapeutic potential of targeting Tumor necrosis factor ligand superfamily member 6 is significant. Exploring its mechanisms could lead to novel treatments for autoimmune disorders and enhance our understanding of immune tolerance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.